Evaluation of mutations in advanced ER+/HER2-breast cancer in Portugal - U-PIK Project.

Around 40% of ER+/HER2-breast carcinomas (BC) present mutations in the gene. Assessment of mutational status is required to identify patients eligible for treatment with PI3Kα inhibitors, with alpelisib currently the only approved tyrosine kinase inhibitor in this setting. U-PIK project aimed to conduct a ring trial to validate and implement the mutation testing in several Portuguese centers, decentralizing it and optimizing its quality at national level.

Cervical Lymph Node Schwannoma-An Unexpected Diagnosis.

Introduction: Schwannomas-Schwann cells-originating tumors-may develop in many locations. However, primary schwannomas arising within lymph nodes are extremely rare, with only a few cases described to this date in the English literature. For the intranodal location, most of the cases are described in the abdominal cavity.